Drug Profile
Botulinum antitoxin heptavalent - Emergent BioSolutions
Alternative Names: BAT; Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)(Equine); H-BAT™Latest Information Update: 07 Jan 2022
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Developer Emergent BioSolutions
- Class Antibacterials; Antitoxins; Immunoglobulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Botulism
Most Recent Events
- 12 Feb 2021 Registered for Botulism in Singapore, Ukraine (IV) before February 2021
- 31 Mar 2017 Emergent BioSolutions signs a modification to its contract with the Biomedical Advanced Research and Development Authority for manufacturing of botulinum antitoxin heptavalent
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions